CATL Stock Hits Record High After Q1 2025 Earnings Surge 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
BURLINGAME, Calif., April 05, 2016 -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs at the American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016 in New Orleans.
Following are the specifics for Corvus’ two poster presentations:
- Inhibition of Adenosine A2A Receptor (A2AR) by CPI-444 Enhances CD8+ T cell Killing of a HER-2/neu Expressing Murine Tumor
| Authored by Blake A. Scott1, Todd Armstrong2, Elizabeth M. Jaffee2 |
| Affiliations: 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Experimental and Molecular Therapeutics |
| Session Date/ Time: Sunday, Apr 17, 1:00 PM – 5:00 PM |
| Location: Morial Convention Center, Halls G-J, Poster Section 17, Poster Board 1 |
- The Adenosine A2A Receptor Antagonist, CPI-444, Blocks Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Alone and In Combination with Anti-PD-1 and Anti-PD-L1
| Authored by Stephen Willingham1, Po Y. Ho1, Robert Leone2, Emily Piccione1, Carmen Choy1, Andrew Hotson1, Joseph Buggy1, Jonathan Powell2, Richard Miller1 |
| Affiliations: 1Corvus Pharmaceuticals, Burlingame, Calif.; 2Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Immunology |
| Session Date/ Time: Monday, Apr 18, 1:00 PM – 5:00 PM |
| Location: Morial Convention Center, Halls G-J, Poster Section 26, Poster Board 21 |
The following oral presentation will take place as follows:
- Adenosine A2a Receptor (A2aR) Antagonist as a Means of Enhancing the Efficacy of Checkpoint Blockade and Adoptive T Cell Therapy
| Authored by Robert D. Leone, Judson M. Englert, Chih-Hsien Cheng, Jiayu Wen, Min-Hee Oh, Im-Hong Sun, Chirag Patel, Ian A. Bettencourt, Jonathan D. Powell |
| Affiliation: Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Immunology |
| Session Date/ Time: Tuesday, Apr 19, 4:20 PM – 4:35 PM |
| Location: Morial Convention Center, New Orleans Theater C |
To learn more about the Corvus pipeline visit http://www.corvuspharma.com/technology/.
ABOUT CORVUS PHARMACEUTICALS
Corvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief Financial Officer [email protected] 650-900-4522 MEDIA CONTACT: Julie Normart, W2O Group 415-946-1087 [email protected]
